These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8130858)

  • 41. Pharmacokinetics of azlocillin in children with and without cystic fibrosis treated for infectious diseases.
    Michalsen H; Bergan T
    Methods Find Exp Clin Pharmacol; 1986 Dec; 8(12):727-9. PubMed ID: 3807473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug disposition in cystic fibrosis.
    Rey E; Tréluyer JM; Pons G
    Clin Pharmacokinet; 1998 Oct; 35(4):313-29. PubMed ID: 9812180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum zinc concentration in cystic fibrosis patients with CFTR I1234V mutation associated with pancreatic sufficiency.
    AbdulWahab A; Abushahin A; Allangawi M; Chandra P; Abdel Rahman MO; Soliman A
    Clin Respir J; 2017 May; 11(3):305-310. PubMed ID: 26096753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Normal spontaneous and stimulated GH levels despite decreased IGF-I concentrations in cystic fibrosis patients.
    Laursen EM; Lanng S; Rasmussen MH; Koch C; Skakkebaek NE; Müller J
    Eur J Endocrinol; 1999 Apr; 140(4):315-21. PubMed ID: 10097250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of potassium bromide in adult horses.
    Raidal SL; Edwards S
    Aust Vet J; 2008 May; 86(5):187-93. PubMed ID: 18454837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative microvascular exchange kinetics of [(77)Br]bromide and (99m)Tc-DTPA in humans.
    Cousins C; Skehan SJ; Rolph SM; Flaxman ME; Ballinger JR; Bird NJ; Barber RW; Peters AM
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):655-62. PubMed ID: 11976804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
    Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bromide as a marker to measure adherence to drug therapy.
    Braam RL; van Uum SH; Russel FG; Swinkels DW; Thien T
    Eur J Clin Pharmacol; 2006 Apr; 62(4):285-90. PubMed ID: 16525815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NTP Toxicology and Carcinogenesis Studies of Triethanolamine (CAS No. 102-71-6) in F344 Rats and B6C3F1 Mice (Dermal Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Nov; 449():1-298. PubMed ID: 12594526
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
    Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
    Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic evaluation of cefsulodin in children with and without cystic fibrosis treated for infectious diseases.
    Michalsen H; Bergan T; Solberg R
    Methods Find Exp Clin Pharmacol; 1986 Nov; 8(11):685-7. PubMed ID: 3807469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Body image and dieting behavior in cystic fibrosis.
    Truby H; Paxton AS
    Pediatrics; 2001 Jun; 107(6):E92. PubMed ID: 11389290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Altered PABA pharmacokinetics in cystic fibrosis. Implications for bentiromide test.
    Koren G; Weizman Z; Forstner G; MacLeod SM; Durie PR
    Dig Dis Sci; 1985 Oct; 30(10):928-32. PubMed ID: 3875462
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral theophylline disposition in cystic fibrosis.
    Georgitis JW; Eigen H; Warner R; Gonzales MA
    Ann Allergy; 1982 Mar; 48(3):175-7. PubMed ID: 7065481
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.
    De Boeck K; Weren M; Proesmans M; Kerem E
    Pediatrics; 2005 Apr; 115(4):e463-9. PubMed ID: 15772171
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of age and intake on vitamin C disposition in females.
    Blanchard J; Conrad KA; Garry PJ
    Eur J Clin Nutr; 1990 Jun; 44(6):447-60. PubMed ID: 2387280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of salivary levels to predict clearance of caffeine in patients with cystic fibrosis.
    Bianchetti MG; Kraemer R; Passweg J; Jost J; Preisig R
    J Pediatr Gastroenterol Nutr; 1988; 7(5):688-93. PubMed ID: 3183872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin resistance is associated with decreased clinical status in cystic fibrosis.
    Hardin DS; LeBlanc A; Lukenbough S; Seilheimer DK
    J Pediatr; 1997 Jun; 130(6):948-56. PubMed ID: 9202618
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and toxicity of bromide following high-dose oral potassium bromide administration in healthy Beagles.
    March PA; Podell M; Sams RA
    J Vet Pharmacol Ther; 2002 Dec; 25(6):425-32. PubMed ID: 12485348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.